Teva Pharmaceutical Industries (TEVA) reported $17.3B in revenue for fiscal 2025, +4.3% year on year. That ranks #324 by revenue among 2853 SEC filers and #36 in Healthcare. Net income was $1.4B, a net margin of 8.2%. Revenue has declined 2.6% a year on average since 2016 ($21.9B then). The fiscal 2025 balance sheet shows $40.7B in total assets, $3.6B in cash and $28.8B in long-term debt.
Key figures
| Key figures | FY2025 | YoY | Source |
|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $17.3B | +4.3% | FY20252025-12-31 |
| Gross profitGrossProfit | $8.9B | +10.8% | FY20252025-12-31 |
| Operating incomeOperatingIncomeLoss | $2.2B | +$2.5B | FY20252025-12-31 |
| Net incomeNetIncomeLoss | $1.4B | +$3.0B | FY20252025-12-31 |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | $1.6B | +32.2% | FY20252025-12-31 |
| Capital expenditurePaymentsToAcquireProductiveAssets | $501M | +0.6% | FY20252025-12-31 |
| Total assetsAssets | $40.7B | +3.6% | FY20252025-12-31 |
| Shareholders' equityStockholdersEquity | $7.9B | +47.2% | FY20252025-12-31 |
| CashCashAndCashEquivalentsAtCarryingValue | $3.6B | +7.8% | FY20252025-12-31 |
| Long-term debtLongTermDebt | $28.8B | −11.4% | FY20172017-12-31 |
Revenue is total net sales for the fiscal year, taken from each company's own annual filing.
Reported since the last full year
Three-month figures this company has filed since FY2025. A quarter is not comparable with a full year, and these figures are used nowhere else on the site: not in any ranking, not in comparisons, not in the download.
| Quarter | Revenue | Net income | Source |
|---|---|---|---|
| Q1 20262026-03-31 | $4.0B | $369M | Open → |
| Q2 20262026-06-30 | $4.1B | −$576M | Open → |
Only periods that end on a calendar quarter appear here. A company whose fiscal year ends in June files on a different calendar, so it has no row.
Where this sits in its sector
Each bar is the spread of the whole sector: the box covers the middle half of companies, the line inside it the median, and the triangle this company. The axis is clipped at the 5th and 95th percentile so a single outlier does not flatten it.
| Where this sits in its sector | FY2025 | Position in sector |
|---|---|---|
| Net marginRank 69 of 161 companies compared | 8.2% | |
| Operating marginRank 71 of 160 companies compared | 12.5% | |
| R&D as share of revenueRank 69 of 102 companies compared | 5.9% | |
| Cash as share of revenueRank 52 of 160 companies compared | 20.6% |
All four are ratios derived from two reported lines, not single filing items. Peer group: companies in the same sector with revenue of $1bn or more; loss-making companies are included.
Profile
- Legal name
- Teva Pharmaceutical Industries LTD
- Ticker
- TEVA
- Exchange
- NYSE
- SIC classification
- Pharmaceutical Preparations (2834)
- Fiscal year end
- 12-31
- CIK
- 0000818686
Filings
- 10-QJul 29, 2026Open filing →
- 10-QApr 29, 2026Open filing →
- 10-KFeb 3, 2026Open filing →
Similar in size, same sector
| Company | Revenue | Net income |
|---|---|---|
| Boston ScientificBSX | $20.1B | $2.9B |
| Universe PharmaceuticalsUPC | $17.9B | −$3.7B |
| Universal Health ServicesUHS | $17.4B | $1.5B |
| Teva Pharmaceutical IndustriesTEVA | $17.3B | $1.4B |
| AflacAFL | $17.2B | $3.6B |
| IQVIA HoldingsIQV | $16.3B | $1.4B |
| Principal FinancialPFG | $15.6B | $1.3B |
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Teva Pharmaceutical Industries — Key figures |url=https://companiesranked.com/en/company/teva-pharmaceutical-industries |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Teva Pharmaceutical Industries — Key figures. CompaniesRanked. https://companiesranked.com/en/company/teva-pharmaceutical-industriesBibTeX
@misc{companiesranked-en-company-teva-pharmaceutical-industries-2026,
author = {{CompaniesRanked}},
title = {{Teva Pharmaceutical Industries — Key figures}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/teva-pharmaceutical-industries}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0001193125-26-034532 · February 3, 2026
{{cite web |title=Teva Pharmaceutical Industries — Key figures — 10-K (0001193125-26-034532) |url=https://www.sec.gov/Archives/edgar/data/818686/000119312526034532/d93612d10k.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-02-03}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.